Alexion Pharmaceutical Inc. diskutieren

Alexion heute an der NASDAQ mit 8% im Plus ohne erkennbaren Newsflow

ValueFreak schrieb am 31.08.20: 

Alexion heute an der NASDAQ mit 8% im Plus ohne erkennbaren Newsflow

 Die EU-Kommission hat Alexion die Erweiterung der bisherigen Zulassung für Soliris (Eculizumab) erteilt: Der monoklonale Antikörper ist ab sofort auch zur Behandlung von Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)* bei erwachsenen Patienten, die positiv für Aquaporin-4(AQP4)-Antikörper sind und einen schubförmigen Krankheitsverlauf zeigen, zugelassen. Damit stellt er die erste und einzige Behandlungsoption dar. 
*  NMOSD sind seltene und schwerwiegende entzündliche Autoimmunerkrankungen des zentralen Nervensystems (ZNS). 

• Robust pipeline of 20+ development programs across 7 rare disease franchises with future plans to continue growing pipeline with >5 novel INDs by 2025
• Increasing depth and breadth of growth opportunities expected to generate 2025 global revenues of $9-10 billion & >10% revenue CAGR through 2025 and beyond
• Expect to raise 2020 full-year revenue guidance by >$200 million
• Robust share repurchase commitment expected to return ~$3 billion cash to shareholders through 2023

• 3Q20 total revenues of $1,588.7 million, a 26% increase over 3Q19
• GAAP diluted EPS was $2.62, compared to $2.08 in the third quarter of 2019
• Non-GAAP diluted EPS was $3.24, compared to $2.79 in the third quarter of 2019.
• Received Japanese approval for ULTOMIRIS® (ravulizumab) in atypical hemolytic uremic syndrome (aHUS)
• Received U.S. approval & positive CHMP opinion for ULTOMIRIS 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & aHUS
• Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS® (eculizumab) in 3 largest markets - U.S., Germany & Japan
• Initiated Phase 3 program for CAEL-101 in AL amyloidosis in collaboration with Caelum Biosciences
• Raised full year guidance, driven by increased revenue guidance of $350 million

AstraZeneca said its cash-and-stock agreement amounts to $175 per Alexion share, based on the one-month average value of AstraZeneca’s U.S.-traded American depositary receipts. The offer is split between $60 in cash and 2.1243 American depositary shares. That represents a 40% premium over Alexion’s one-month share-price average, AstraZeneca said. Alexion’s shares closed Friday at $120.98.